

Effect of Progesterone in Lowering Maternal Plasma Corticotropin-Releasing Hormone in Patients with Preterm Labor

Enas M. Yaseen¹ CABOG, FICOG, Athraa Fadhil Abd² FICOG

¹Dept. of Obstetrics and Gynecology, College of Medicine, Tikrit University, Tikrit, Iraq, ²Dept. of Obstetrics and Gynecology, Samaraa General Hospital, Samaraa, Iraq

Abstract

Background	Preterm labor is a major obstetrics problem because it associated with high morbidity and mortality to the born baby. Many studies were done to study different aspects of its risk factors, diagnosis and treatment to decrease its incidence, bad sequel to the fetus and recurrence.
Objective	To evaluate the role of progesterone in lowering CRH level in plasma of patient with preterm labor.
Methods	This study is a case control study. Forty-five pregnant women with preterm labor were included in the study and basal plasma Corticotropin releasing hormone (CRH) level was done for each patient. All patients were given oral tocolytic drug, with an initial bolus of 20 mg Nifedipine followed by 10 mg three times daily. They received betamethasone injection (12 mg) 24 hours after hospitalization. Then after stabilization of each patient with random selection, 25 patients were included in group (1) and were given progesterone injection. Twenty patients were included in group (2) or control group because no progesterone injection was given to them. After 24 hours of admission to the hospital, plasma CRH level was measured for both groups with evaluation of the outcome of each patient with preterm labor.
Results	Progesterone is more effective in lowering CRH level in patients with preterm labor. In study of 45 cases of preterm labor, the mean CRH level of group (1) decreased from 33.41 ng/ml to 22.12 ng/ml, while the mean level of it in group (2) increased from 27.44 ng/ml to 28.54 ng/ml.
Conclusion	Progesterone treatment is effective in lowering CRH level in patients with preterm labor. This would have a positive effect in prolonging the pregnancy period in these patients.
Keywords	Preterm labor, progesterone, CRH
Citation	Yaseen EM, Abd AF. Effect of progesterone in lowering maternal plasma corticotropin-releasing hormone in patients with preterm labor. Iraqi JMS. 2019; 17(1): 32-42. doi: 10.22578/IJMS.17.1.6

List of abbreviations: ACTH = Adrenocorticotropin hormone, 17OHPG = 17 Alpha hydroxyprogesterone caproate, CRH = Corticotropin releasing hormone, CRH1, CRH2 = Corticotropin releasing hormone receptors, CS = Cesarean section, DCs = Dendritic cells, HCG = Human chorionic gonadotropin, NCIU = Neonatal care intensive unit, NK = Natural killer, PGDH = Prostaglandin dehydrogenase, PR-A, PR-B = Progesterone receptors, PTL = Preterm labor, RDS = Respiratory distress syndrome, Th2 = T-helper cell type 2

Introduction

Preterm labor occurs when there is frequent, regular uterine contraction and cervical dilation before 37 weeks of gestation. The incidence of preterm labor in developed world between 7 to 12% ⁽¹⁾. There has been a small gradual rise in the incidence of

preterm labor associated with assisted reproduction and an increased tendency to obstetric intervention. The rate of preterm labor prior to 32 weeks has remained relatively stable at 1-2% ^(1,2).

The mortality, morbidity and costs of preterm labor are higher at lower gestational ages, there is a high risk of short - and long-term morbidity ⁽³⁾.

Three potential causal pathways leading to preterm delivery have been identified: infection - cervical pathway, placental - vascular pathway and stress - strain pathway. these factors

provide a direction for the identification of patient at risk and the application of potential interventions ^(4,5). Pathogenesis of it includes idiopathic: preterm labor of unknown etiology accounts for 60-70% of it ⁽⁶⁾. Labor due to premature activation of hypothalamic/pituitary/adrenal axis. Infection: there is a strong correlation between infection within the uterus and the onset of spontaneous labor ^(7,8), hemorrhage, placental abruption and uterine over distension ⁽²⁾.

Corticotropin-releasing hormone (CRH) is a 41 amino acid peptide hormone in the hypothalamus. It regulates adrenocorticotropin hormone (ACTH) secretion in the anterior pituitary which signals adrenal gland to release cortisol that has powerful metabolic and anti-inflammatory effects ^(9,10). Physical or psychological events stimulate secretion of CRH, which co-ordinates neuroendocrine response to stress because it acts as a neuro-transmitter in some regions of the central nervous system. It produced in a variety of tissues outside the central nervous system, including the gut, ovary, testis, fetal membranes maternal and fetal blood, amniotic fluid and placenta during pregnancy with large amounts of CRH in comparison to non-pregnant ⁽¹¹⁾.

It is now well established that the concentrations of CRH in maternal blood rise progressively during pregnancy ^(12,13). This rise correlates with increased levels of CRH mRNA and CRH peptide in placental tissue ⁽¹⁴⁾. In the circulation, CRH is largely associated with a high-affinity circulating CRH-binding protein (CRH-BP) produced in the liver, placenta and at other sites, including the brain. CRH-BP effectively blocks the action of placental CRH on the maternal pituitary gland and on the myometrium. Near term, and in association with preterm labor, CRH-BP concentrations fall, coincident with the increase in circulating CRH ⁽¹³⁾.

Many factors regulate placental CRH output and has been reviewed extensively ⁽¹²⁾. Estrogens, progesterone, and nitric oxide inhibit CRH production, while number of neuropeptides

exert a stimulatory effect ⁽¹²⁾, also, glucocorticoids, prostaglandins, cytokines and catecholamine increase it. Karalis and Majzoub suggested that the inhibitory effect of progesterone is exerted through binding to CRH receptor in trophoblastic cells. At term, increased levels of cortisol displace progesterone bound to GRH receptors and this will lead to an increase in CRH output. Thus, the mechanism of interaction between progesterone and cortisol in the regulation of CRH is similar to that proposed for the regulation of enzyme 15-hydroxy prostaglandin dehydrogenase (PGDH) ⁽¹⁵⁾.

In spite of the fact that CRH binding protein (CRHBP) decreases in maternal circulation before labor, placental CRHBP mRNA expression remain unchanged. This leads to the hypothesis that another source of CRHBP exists, such as a fetal source that may be responsible for this decrease ^(16,17).

The functional target of placental CRH is not the maternal pituitary adrenal axis but the fetal pituitary adrenal axis ⁽¹⁸⁾. Placental CRH stimulate ACTH production from the fetal pituitary. ACTH stimulates fetal adrenals to produce dehydroepiandrosterone (DHEA), dehydroepiandrosterone-sulphate (DHEA-S), and cortisol. ACTH is also produced in the placenta through paracrine mechanisms. Fetal adrenal DHEA is metabolized to estrogens in the placenta that favor parturition ^(11,19,20). The produced cortisol exerts a stimulatory effect on the placenta to further produce CRH, thus a positive loop is established that causes placental CRH to rise exponentially as pregnancy advances ⁽¹¹⁾.

CRH has two receptors, specific receptors, termed CRH-R1 and CRH-R2 ⁽²¹⁾. The expression of CRH-R2 protein increased toward onset of labor increases myometrial contractility ⁽²²⁾. Both types of receptors have been identified in the upper and lower uterine segment of contracting human myometrium, but during labor CRH-R1 decreases significantly at the upper segment but not at the lower one. This will explain the fact during labor the fundus of

the uterus switches to a highly contractile state, while the lower segment remains relatively quiescent ⁽²³⁾.

Studies of preterm labor aimed to give time to steroid to take its action and current evidence shows that a single course of maternal steroids given between 24 and 34 weeks gestation and received within 7 days of delivery results in markedly improved neonatal outcomes, with a significant reduction in rate of respiratory distress syndrome, neonatal death, intraventricular hemorrhage ^(1,2).

Progesterone is a vital gestational-support steroid hormone that belongs to the C21 group of progestagens produced in the adrenal glands, corpus luteum in non-pregnant and in pregnant till 10 weeks of gestational age, brain and placenta ⁽²⁴⁾.

Progesterone modulates immune reaction of maternal body against embryo and fetus by anti-inflammatory effects throughout pregnancy. It inhibits the activity of dendritic cells (DCs) that generate proinflammatory responses and help the process of tolerogenic DCs. It limits the action of natural killer (NK) cells and the differentiation of T cells into T-helper cell type 2 (Th2) like clones which maintain pregnancy ^(25,26).

According to the "progesterone block" hypothesis, proposed by Csapo, progesterone blocks myometrial contraction and maintains pregnancy, while its withdrawal transforms the myometrium to the delivery state ⁽²⁷⁾.

However, in humans, progesterone levels remain high throughout pregnancy and during labor ⁽²⁸⁾. This has led to the hypothesis of a "functional" progesterone withdrawal that may occur ⁽²⁹⁾. In human myometrial cells, the ratio of PR-A:PR-B mRNA increases 2- to 3-fold compared with the non-laboring state, mainly due to over expression of PR-A which induces "functional estrogen activation" through increased estrogen receptor α (ER α) expression ⁽³⁰⁾. PR-A may also suppress the transcriptional activity of PR-B, which is the main receptor for the nuclear signal transduction of progesterone ^(31,32). Apart from myometrial contractions, the

functional progesterone withdrawal due to the altered expression of PR-A, PR-B isoforms may also contribute to the cervical changes during labor ^(33,34).

While the exact mechanism of action of progestogens in preventing preterm labor is unknown, several possibilities have been proposed; in summary by two mechanisms; either anti-inflammatory effect, or local increase in progesterone in gestational tissues ⁽³⁵⁻⁴¹⁾ as it may act on prevention of gap junctions formation which inhibits myometrial contractions and prevent spontaneous early miscarriage and preterm labor (PTL) ⁽⁴²⁾.

Progestins are available in natural or synthetic formulations for oral intramuscular or vaginal rout in the form of suppository or gel. Natural (micronized) progesterone is an exact duplicate of the progesterone produced in the corpus luteum and placenta. It is therefore more readily metabolized by the body and is associated with minimal side effects.

17 alpha hydroxylprogesterone caproate (17OHP) is 17-hydroxyprogesterone derivative; it is the most commonly used synthetic progestin given intramuscularly to prevent PTL. It has been isolated from both adrenal glands and corpora lutea. The synthetic caproate ester works as a long-acting progestin when administered intramuscularly for 7-8 days with peak plasma concentration is about 2-8 hours. The most common undesirable side effects were injection site pain, injection site swelling urticarial, pruritis, nausea, contusion, injection site nodule and vomiting ⁽⁴³⁾.

The aim of this study is to evaluate the role of progesterone in lowering CRH level in plasma of patient with preterm labor.

Methods

This study is a case control study. It was conducted at Tikrit Teaching Hospital – Department of Obstetrics and Gynecology from January 2013 to January, 2014. This study was approved by the Ethical Committee of the Iraqi Scientific Council for Medical Specialization- Department of Obstetrics and Gynecology. The

informed consent was taken from each patient. Women with preterm labor between 24-34 weeks of gestation were included in the study.

Inclusion criteria

- Single life pregnancy.
- Intact membranes.
- No cerclage.
- Cervical dilation of equal or <2 cm.

Exclusion criteria

- Signs of infection (urinary tract infection, chorioamnionitis).
- Medical diseases.
- Contraindication to tocolysis.
- Adverse reaction to progesterone or any component of the formulation (by history).
- Progesterone treatment within 4 weeks before enrollment.
- History or suspicion of breast or genital tract malignancy.
- Evidence of intra-uterine reconstructions, or congenital anomalies in ultrasound.

At admission full history, general and obstetrical examination, maternal vital signs (blood pressure, temperature, pulse rate, respiratory rate) and cardiotocography (fetal heart rate assessment, uterine contraction) was done to each patient.

All patients had urine examination, high vaginal swab for culture and sensitivity to exclude genital tract infection and complete blood picture. CRH level was measured in each patient in both groups by: drawing venous blood (4-5 mL) into a tube that contained the anticoagulant sodium citrate. This assay employed by the competitive inhibition enzyme immune assay technique. The kit manufactured by



All patients were given oral tocolytic, with an initial bolus of 20 mg Nifedipine followed by 10 mg three times daily. After hospitalization they received betamethasone injection (12 mg) in two divided doses during 24 hours. After patient's condition stabilization with random selection, 25 of them received intramuscular Hydroxyprogesterone Caproate 250 mg (Bayer)

and they were classified as group (1). They received this injection weekly till 36 completed weeks or earlier if they delivered. The remaining patients who received no progesterone injection were classified as group (2) or control groups.

Observation of each patients were done including: blood pressure, pulse rate, uterine contraction, fetal heart rate; and any other maternal side effects as headache hypotension, nausea, vomiting, injection site reaction, purities, and vaginal discharge. After 24 hours of progesterone injection, plasma CRH level was measured gain.

All patients followed up till delivery in outpatient clinic. Detection Range was between 1.6- 40 ng/ml.

Statistical analysis and data management

The Statistical Package for Social Sciences (SPSS, version 18) was used for data entry and analysis. Chi (χ^2) square test, unpaired Student t test, Paired t- test, one –way ANOVA and Pearson correlation was used to complete statistical analysis. Odds ratio used to test the risk. P value of ≤ 0.05 was regarded as statistically significant.

Results

Patient's general characteristics are shown in (Table -1).

Figure (1) and (2) show the relation between parity, gravida and basal plasma CRH levels. The level of them increases in a significant moderate positive linear correlation with the parity and gravida increment.

Table 1. General characteristics of patient with preterm labor

Study group characteristics		Mean	SD
Gravid		3.69	2.29
Para		2.13	1.59
Abortion		0.56	1.06
Gestational age		31.13	2.63
Gestational age of delivery		34.93	3.45
Basal plasma CHR level		30.76	8.41
Plasma CHR after 24 hr		24.97	12
		Frequency	Percent
History of preterm labor	Yes	6	13.3%
	No	39	86.7%
Cause of preterm	Negative	39	86.6%
	Infection	3	6.7%
	Idiopathic	3	6.7%
Antenatal care	Yes	29	64.4%
	No	16	35.6%
Mode of delivery	NVD	35	77.8%
	CS	10	22.2%
Total		45	100%




Figure 1. Correlation between parity and basal plasma CHR level




Figure 2. Correlation between Gravida and basal plasma CRH level

The mean level of CRH level decreased after 24hr due to progesterone injection in group (1), while it increased in group (2) (Table 2).

Sixty eight percent of group (1) delivered at term or near term while only 45% of group (2) delivered at this time. The odds ratio to deliver within 2 weeks for the group (2) was 2.597 times more than group (1). The relative risk of group

(2) was 1.7 to deliver within 2 weeks, while for the group (1) was 0.6 (Table 3).

Table (4) shows a decrease in mean plasma CRH level after 24hr of treatment in all patients of group (1). Its mean is increasing in group (2) for those who delivered within 2weeks, while it is decreasing slightly for those who delivered at term or near term.

Table 2. The mean level of CRH level among study groups at base line and after 24 hr of treatment

CRH levels	Group (1)			Group (2)			Independent t-test P value
	Mean	SD	SE	Mean	SD	SE	
Basal CRH level	33.41	4.40	0.88	27.44	10.89	2.43	<0.05
CRH (after 24 hr)	22.12	12.88	2.58	28.54	10.00	2.24	>0.05
Paired t-test P value	<0.05			>0.05			

Table 3. The risk and odds ratio of preterm labor

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for time delivery (within 2 week / reach term or near term)	2.597	0.769	8.775
Risk of deliver within 2 weeks for group (1)	0.644	0.355	1.170
Risk of deliver within 2 weeks for group (2)	1.673	0.871	3.213

Table 4. The mean plasma CRH level in both groups according to the delivery time

Out -come of treatment		Group (1)			Group (2)		
		Basal plasma CRH level	Plasma CRH level after 24 hr	Paired t- test	Basal plasma CRH level	Plasma CRH level after 24 hr	Paired t- test
Delivery within 2 weeks	Mean	34.54	31.15	<0.05	22.98	25.87	<0.05
	SD	4.98	4.97		11.57	11.26	
	SE	1.76	1.76		3.49	3.39	
	Minimum	26.60	25.30		2.00	4.00	
	Maximum	38.65	37.20		34.00	35.50	
	No.	8	8		11	11	
Reach term/ near term	Mean	32.87	17.87	<0.05	32.89	31.80	<0.05
	SD	4.16	13.34		7.32	7.57	
	SE	1.01	3.23		2.44	2.52	
	Minimum	23.00	2.00		25.70	23.40	
	Maximum	37.33	32.60		46.00	45.00	
	No.	17	17		9	9	
Independent t-test		> 0.05			<0.05		

Table (5) shows no statistical differences in mode of delivery in both groups. While there is significant in neonatal out comes such as:

admission to neonatal care intensive unit (NCIU) (40%) of group (1) and only (85%) of group (2) had admission to NCU.

Table 5. The mode of delivery and neonatal outcomes in both groups

		Group (1)		Group (2)		P value
		No.	Percent	No.	Percent	
Mode of delivery	NVD	17	68%	18	90%	>0.05
	CS	8	32%	2	10%	
Neonatal out come	no admission	15	60 %	3	15%	<0.05
	< 7 days	7	28%	10	50%	
	> 7 days	3	12%	7	35%	
Causes of admission	RDS	3	12%	5	25%	>0.05
	hyperbilirubinemia	2	8%	4	20%	
	septicemia	2	8%	3	15%	
	Convulsion	1	4%	2	10%	
	Others	2	8%	3	15%	
Total		25	100%	20	100%	

Discussion

Preterm birth (PTB) occurs when delivery before 37+0 weeks of gestation and it is the most important single determinant of adverse infant outcome in terms of both survival and quality of life. Gestational age determines preterm outcomes such as death or neurosensory defects, huge psychosocial and emotional effects on the family and cost of health services ⁽⁴⁴⁾.

Many tocolytic drugs suppress myometrium contractions such as beta-agonists, calcium channel blockers, oxytocin receptor antagonists, prostaglandin synthetase inhibitors, nitric oxide donors and magnesium sulphate. There is little reliable information about current clinical practice but it is likely that the use of the beta-agonist ritodrine hydrochloride, which was widespread in the past, has declined. Magnesium sulphate is popular for tocolysis in the USA and some other parts of the world but has rarely been used for this indication in the UK ⁽⁴⁵⁾.

Of all treatments evaluated for the prevention of spontaneous PTB to date, progestational agents have demonstrated the greatest promise. Progesterone supplement therapy is one of the few proven effective methods to prevent PTB in women with history of spontaneous PTB and in women with short corpus luteal phase. There are 2 types of progesterone therapy currently used for prevention of PTB: weekly intramuscular

injection of 17-alpha hydroxyprogesterone caproate and daily administration of natural micronized progesterone vaginal gel, vaginal suppository, or oral capsule ⁽⁴⁶⁾.

Progesterone and CRH play an important role in pregnancy and labor, so their changes affect transition from myometrial quiescence to contractility ⁽²⁷⁾. In this study, evaluation of the effect of progesterone on CRH, which is the main player in initiation of labor was done.

Our study showed that progesterone treatment has more effect in decreasing CRH level than tocolytics. This result affects the time of delivery.

In a new study done by Khazaali (2018) in Iraq the author found that a significant reduction in preterm delivery rate among women receiving progesterone vaginal suppositories and there was significant reduction in the frequency of respiratory distress syndrome, low birth weight neonates and admissions to neonatal intensive care unit in women taking vaginal progesterone pessary compared to the control ⁽⁴⁷⁾.

Also, there are several studies demonstrates the relation of CRH and progesterone on labor. Vrachnis et al in 2012 explained immune and myometrial effects of progesterone and CRH in Labor because both modify immune response during pregnancy and progesterone withdrawal encourages inflammatory pathways. In labor, withdrawal of progesterone occurs by with metabolic changes of progesterone, receptors changes, and other factors or enzymes that

stimulate or inhibit progesterone. Placental CRH acts on the fetal pituitary-adrenal axis to stimulate adrenal production of androgens and cortisol and also acts directly on myometrial cells via its receptors ⁽²⁷⁾.

Regmi et al in 2012 conducted a study of progesterone for Prevention of recurrent preterm labor after arrested it. Progesterone reduces preterm labor recurrence significantly but neonatal outcomes unchanged in between groups ⁽⁴²⁾.

A meta-analysis of nine studies by Coomarasamy et al in 2006 showed the effectiveness of progesterone in the prevention of preterm labor by in suspected patients and reduction in neonatal respiratory complications ⁽⁴⁸⁾.

Mackenzie et al in 2006 conducted a meta-analysis evaluating the use of progesterone for high risk women with PTB. Again, progesterone prophylaxis reduces incidence of preterm labor without significant reduction in neonatal complications ⁽⁴⁹⁾. This agree with our results.

Kurki et al in 1991 measured maternal plasma CRH in preterm patients before and after given indomethacin or nylidrin, they showed a 10% decrease in the indomethacin group and 10-20% decrease in the nylidrin group, but these changes were not statistically significant ⁽⁵⁰⁾.

Our results were promising regarding clinical and biochemical effectiveness of progesterone in lowering the level of CRH in patients of PTL. The changing in CRH level has positive effect in delaying the labor till term or near term.

We recommend larger studies are needed to study the level of CRH according to different maternal characteristics in preterm labor. Using progesterone in combination with other tocolytic drugs as new combinations of drugs in hope that increasing their effectiveness in treatment of PTL and possibilities in using this combination in multiple pregnancies.

Acknowledgments

Authors would like to thanks all the doctor and staff of Tikrit Teaching Hospital for their help.

Author contribution

Dr. Abd: collection of data, statistical analysis and writing the first draft of manuscript, and both authors made the final draft of manuscript.

Conflict of interest

No conflict of interest.

Funding

No financial support to this study.

References

1. Bennett P, Edmond K. Preterm Labor. Dewhurst's textbook of obstetrics and gynecology for postgraduates. 7th ed. Blackwell Science Ltd; 2007. p. 177-91.
2. Taylor M, Rundle S. Preterm labor. In: Luesly DM, Kilby MD (eds). An evidence-based text for MRCOG in obstetrics and gynecology, 3rd ed. CRC Press; 2006. p. 327-37.
3. Cunningham FG, Leveno K, Bloom S, et al. Williams Obstetric. Textbook, 23rd ed. MacGraw Hill; 2010. p. 804-8.
4. Hacker NP, Moore JC. Obstetrics complications: Obstetric Complications: Preterm Labor, PROM, IUGR, Postterm Pregnancy, and IUFD. In: Hacker NP, Gambone JC (eds). Hacker and Moore Essential of Obstetrics and Gynecology. Philadelphia: Elsevier, Saunders; 2004. p. 167-82.
5. Romero R, Espinoza J, Erez O, et al. The role of cervical cerclage in obstetric practice: can the patient who could benefit from this procedure be identified? Am J Obstet Gynecol. 2006; 194(1): 1-9. doi: 10.1016/j.ajog.2005.12.002.
6. ACOG Committee on Practice Bulletins--Obstetrics. ACOG practice bulletin. Management of preterm labor. Number 43, May 2003. Int J Gynaecol Obstet. 2003; 82(1): 127-35.
7. Goldenberg RL, Andrews WW, Hauth JC. Choriodecidual infection and preterm birth. Nutr Rev. 2002; 60(5 Pt 2): S19-25. doi: 10.1301/00296640260130696.
8. Goncalves LF, Chaiworapongsa T, Romero R. Intrauterine infection and prematurity. Ment Retard Dev Disabil Res Rev. 2002; 8(1): 3-13. doi: 10.1002/mrdd.10008.
9. Challis JRG. Fetal endocrine signals and preterm labor. Biol Neonate. 2001; 79(3-4): 163-7. doi: 10.1159/000047085.
10. Whittle WL, Patel FA, Alfaidy N, et al. Glucocorticoid regulation of human and ovine parturition: The relationship between fetal hypothalamic-pituitary-adrenal axis activation and intrauterine prostaglandin production. Biol Reprod. 2001; 64(4): 1019-32.
11. Smith R: Parturition. N Engl J Med. 2007; 365: 271-83. doi: 10.1056/NEJMra061360.
12. Petraglia F, Florio P, Nappi C, et al. Peptide signaling in human placenta and membranes: autocrine,

- paracrine and endocrine mechanisms. *Endocr Rev.* 1996; 17(2): 156-86. doi: 10.1210/edrv-17-2-156.
13. Linton EA, Perkins AV, Woods RJ, et al. Corticotropin releasing hormone- binding protein (CRH-BP); plasma levels decrease during the third trimester of normal human pregnancy. *J Clin Endocrinol Metab.* 1993; 76(1): 260-2. doi: 10.1210/jcem.76.1.8421097.
 14. Frim DM, Emmanuel RL, Robinson BG, et al. Characterization and gestational regulation of corticotropin-releasing hormone messenger RNA in human placenta. *J Clin Invest.* 1988; 82(1): 287-92. DOI: 10.1172/JCI113585.
 15. Karalis K, Majzoub JA. Regulation of placental corticotrophin-releasing hormone by steroids. Possible implications in labor initiation. *Ann N Y Acad Sci.* 1995; 771: 551-5.
 16. McLean M, Bisits A, Davies J, et al. A placental clock controlling the length of human pregnancy. *Nat Med.* 1995; 1(5): 460-3.
 17. Torricelli M, Giovannelli A, Leucci E, et al. Labor (term and preterm) is associated with changes in the placental mRNA expression of corticotrophin-releasing factor. *Reprod Sci.* 2007; 14(3): 241-5. DOI: 10.1177/1933719107300971.
 18. McLean M, Smith R. Corticotrophin-releasing hormone and human parturition. *Reproduction.* 2001; 121(4): 493-501. doi: <http://dx.doi.org/10.1530/rep.0.1210493>.
 19. Sirianni R, Mayhew BA, Carr BR, et al. Corticotropin-releasing hormone (CRH) and urocortin act through type 1 CRH receptors to stimulate dehydroepiandrosterone sulfate production in human fetal adrenal cells. *J Clin Endocrinol Metab.* 2005; 90(9): 5393-400. doi: 10.1210/jc.2005-0680.
 20. Mesiano S, Welsh TN. Steroid hormone control of myometrial contractility and parturition. *Semin Cell Dev Biol.* 2007; 18(3): 321-31. doi: 10.1016/j.semcdb.2007.05.003.
 21. Hillhouse EW, Grammatopoulos DK. The molecular mechanisms underlying the regulation of the biological activity of corticotropin-releasing hormone receptors: implications for physiology and pathophysiology. *Endocr Rev.* 2006; 27(3): 260-86. doi: 10.1210/er.2005-0034.
 22. Grammatopoulos DK. Placental corticotrophin-releasing hormone and its receptors in human pregnancy and labor: still a scientific enigma. *J Neuroendocrinol.* 2008; 20(4): 432-8. doi: 10.1111/j.1365-2826.2008.01660.x.
 23. Cong B, Zang L, Gao L, et al. Reduced expression of CRH receptor type 1 in upper segment human myometrium during labor. *Reprod Biol Endocrinol.* 2009; 7: 43. doi: 10.1186/1477-7827-7-43.
 24. Speroff L, Glass RH, Kase NG. Clinical gynecologic endocrinology and infertility. 5th ed. Baltimore: Williams and Wilkins; 1994. p. 842.
 25. Szekeres-Bartho J, Halasz M, Palkovics T. Progesterone in pregnancy; receptor-ligand interaction and signaling path- ways. *J Reprod Immunol.* 2009; 83(1-2): 60-4. doi: 10.1016/j.jri.2009.06.262.
 26. Raghupathy R. Th1-type immunity is incompatible with successful pregnancy. *Immunol Today.* 1997; 18(10): 478-82.
 27. Csapo A. Progesterone block. *Am J Anat.* 1956; 98(2): 273-91.
 28. Mitchell BF, Taggart MJ. Are animal models relevant to key aspects of human parturition? *Am J Physiol Regul Integr Comp Physiol.* 2009; 297(3): R525-45. doi: 10.1152/ajpregu.00153.2009.
 29. Mendelson CR. Mini review: fetal-maternal hormonal signaling in pregnancy and labor. *Mol Endocrinol.* 2009; 23(7):947-54. doi: 10.1210/me.2009-0016.
 30. Mesiano S, Chan EC, Fitter JT, et al. Progesterone withdrawal and estrogen activation in human parturition are coordinated by progesterone receptor A expression in the myometrium. *J Clin Endocrinol Metab.* 2002; 87(6): 2924-30. doi: 10.1210/jcem.87.6.8609.
 31. Giangrande PH, Kimbrel EA, Edwards DP, et al. The opposing transcriptional activities of the two isoforms of the human progesterone receptor are due to differential cofactor binding. *Mol Cell Biol.* 2000; 20(9): 3102-15. doi: 10.1128/MCB.20.9.3102-3115.2000.
 32. Merlino AA, Welsh TN, Tan H, et al. Nuclear progesterone receptors in the human pregnancy myometrium: evidence that parturition involves functional progesterone withdrawal mediated by increased expression of progesterone receptor-A. *J Clin Endocrinol Metab.* 2007; 92(5): 1927-33. doi: 10.1210/jc.2007-0077
 33. Stjernholm-Vladic Y, Wang H, Stygar D, et al. Differential regulation of the progesterone receptor A and B in the human uterine cervix at parturition. *Gynecol Endocrinol.* 2004; 18(1): 41-6. doi: <http://dx.doi.org/10.1080/09513590310001651777>.
 34. Vladic-Stjernholm Y, Vladic T, Blesson CS, et al. Prostaglandin treatment is associated with a withdrawal of progesterone and androgen at the receptor level in the uterine cervix. *Reprod Biol Endocrinol.* 2009; 7: 116. doi: 10.1186/1477-7827-7-116.
 35. Renthall NE, Chen CC, Williams KC, et al. miR-200 family and targets, ZEB1 and ZEB2, modulate uterine quiescence and contractility during pregnancy and labor. *Proc Natl Acad Sci U S A.* 2010; 107(48): 20828-33. doi: 10.1073/pnas.1008301107.
 36. Briery CM, Veillon EW, Klauser CK, et al. Women with preterm premature rupture of the membranes do not benefit from weekly progesterone. *Am J Obstet Gynecol.* 2011; 204(1): 54.e1-5. doi: 10.1016/j.ajog.2010.08.022.
 37. Zakar T, Mesiano S. How does progesterone relax the uterus in pregnancy? *N Engl J Med.* 2011; 364(10): 972-3. doi: 10.1056/NEJMcibr1100071.
 38. Peltier MR, Tee SC, Smulian JC. Effect of progesterone on proinflammatory cytokine production by monocytes stimulated with pathogens associated with preterm birth. *Am J Reprod Immunol.* 2008;

- 60(4): 346-53. doi: 10.1111/j.1600-0897.2008.00633.x.
39. Xu H, Gonzalez JM, Ofori E, et al. Preventing cervical ripening: the primary mechanism by which progestational agents prevent preterm birth? *Am J Obstet Gynecol.* 2008; 198(3): 314. e1-8. doi: 10.1016/j.ajog.2008.01.029.
 40. Sfakianaki AK, Norwitz ER. Mechanisms of progesterone action in inhibiting prematurity. *J Matern Fetal Neonatal Med.* 2006; 19(12): 763-72. doi: 10.1080/14767050600949829.
 41. O'Brien JM, DeFranco EA, Adair CD, et al. Effect of progesterone on cervical shortening in women at risk for preterm birth: secondary analysis from a multinational, randomized, double-blind, placebo-controlled trial. *Ultrasound Obstet Gynecol.* 2009; 34(6): 653-9. doi: 10.1002/uog.7338.
 42. Regmi MC, Rijal P, Agrawal A, et al. Progesterone for prevention of recurrent preterm labor after arrested preterm labor - a randomized controlled trial. *Gynecol Obstet.* 2012; 2: 125. doi: 10.4172/2161-0932.1000125.
 43. How HY, Sibai BM. Progesterone for the prevention of preterm birth: indications, when to initiate, efficacy and safety. *Ther Clin Risk Manag.* 2009; 5(1): 55-64.
 44. Sigal S, Doyal LW. An overview of mortality and sequel of preterm birth from infancy to adulthood. *Lancet.* 2008; 371(9608): 261-9. doi: 10.1016/S0140-6736(08)60136-1.
 45. Royal College of Gynecology and Obstetrics. Green-top Guideline. Tocolysis for Women in Preterm Labour. No. 1b; 2011: 1.
 46. Choi SJ. Use of progesterone supplement therapy for prevention of preterm birth: review of literatures. *Obstet Gynecol Sci.* 2017; 60(5): 405-420. doi: 10.5468/ogs.2017.60.5.405.
 47. Khazaali EAA. Vaginal progesterone pessary for preterm labor prevention in women with short cervix early in the second trimester. *Iraqi JMS;* 2018; 16(2): 133-43. doi: 10.22578/IJMS.16.2.4.
 48. Coomarasamy A, Thangaratnam S, Gee H, et al. Progesterone for the prevention of preterm birth: A critical evaluation of evidence. *Eur J Obstet Gynecol. Reprod Biol.* 2006; 129: 111-8. doi: 10.1016/j.ejogrb.2006.05.013.
 49. Mackenzie R, Walker M, Armson A, et al. Progesterone for the prevention of preterm birth among women at increased risk: A systematic review and meta-analysis of randomized controlled trials. *Am J Obstet Gynecol.* 2006; 194(5): 1234-42. doi: 10.1016/j.ajog.2005.06.049.
 50. Kurki T, Laatikainen T, Salminen-Lappalainen K, et al. Maternal plasma corticotrophin-releasing hormone--elevated in preterm labor but unaffected by indomethacin or nylidrin. *Br J Obstet Gynecol.* 1991; 98(7): 685-91.

Correspondence to Dr.Enas M. Yaseen

E-mail: enasyaseen51@yahoo.com

Received Jun. 21st 2018

Accepted Dec. 5th 2018